Keros Therapeutics, Inc.
NASDAQ:KROSBiotechnology
+$0.13 today
- Market cap
- $235.49M
- Beta
- 0.96
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.29
Volume 0.55M
Average 0.36M
KROS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Keros Therapeutics, Inc.NASDAQ: KROS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $6.2M fell 30.1% year over year, behind the -27.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 15.1% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.
Context
- Stock-based compensation amounted to 11.8% of revenue in FY2025, down 970.6 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -30.1% toward the trailing-twelve-month pace of -27.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 28.7M USD
- Year-over-year change
- -17.7%
- 4-year CAGR
- +25.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.7M | -17.7% |
| FY2024 | 2024-12-31 | 34.87M | +21.2% |
| FY2023 | 2023-12-31 | 28.76M | +54.0% |
| FY2022 | 2022-12-31 | 18.68M | +59.4% |
| FY2021 | 2021-12-31 | 11.72M | — |
Stock-Based Compensation vs competitors
How KROS compares with its peers on the latest reported figures
- KROS's LTM Mar 2026 stock-based compensation of $26.03M is the 2nd largest of the 10 companies compared; the peer median is $12.84M.
- Its year-over-year change of -27.0% is the 9th highest of 10, against a peer median of +21.4%.
- Stock-based compensation amounts to 78.5% of revenue for KROS, versus a peer median of 22.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.64M | -7.4% | -5.4% | 39.4% | |
| LTM Mar 2026 | $26.03M | -27.0% | +15.4% | 78.5% | |
| LTM Mar 2026 | $23.96M | +203.5% | +10.1% | — | |
| LTM Mar 2026 | $13.53M | -11.4% | +13.5% | 737.0% | |
| LTM Mar 2026 | $13.21M | -40.1% | — | — | |
| LTM Mar 2026 | $12.84M | +21.4% | +0.9% | 4.3% | |
| LTM Mar 2026 | $9.66M | +26.4% | +15.9% | 19.5% | |
| LTM Mar 2026 | $9.12M | +17.3% | -21.7% | 25.6% | |
| LTM Mar 2026 | $6.73M | +88.8% | +25.6% | — | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | $6.71M | +79.0% | +1.9% | 5.1% |
| Peer median (excluding KROS) | $12.84M | +21.4% | +6.0% | 22.6% | |
Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.74M) | (104.68M) | (152.99M) | (187.35M) | 87.01M |
| Depreciation & Amortization | 378K | 674K | 815K | 1.23M | 1.51M |
| Deferred Income Tax | 46K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.72M | 18.68M | 28.76M | 34.87M | 28.7M |
| Change in Working Capital | (16.07M) | 14.31M | (2.65M) | (11.44M) | (12.11M) |
| Accounts Receivables | (18M) | 18M | (143K) | (2.6M) | (825K) |
| Inventory | 1.04M | 0 | (4.51M) | 0 | 0 |
| Accounts Payables | 1.49M | (408K) | 1.61M | (249K) | (3M) |
| Other Working Capital | (597K) | (3.28M) | 384K | (8.59M) | (8.29M) |
| Other Non-Cash Items | 520K | 953K | 1.56M | 1.82M | 2.4M |
| Operating Cash Flow | (62.15M) | (70.06M) | (124.51M) | (160.87M) | 107.51M |
| Capital Expenditures | (1.02M) | (1.24M) | (2.46M) | (1.93M) | (1.55M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.02M) | (1.24M) | (2.46M) | (1.93M) | (1.55M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 28.17M | 119.58M | 175.83M | 380.13M | (3.47M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (375M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 379K | 731K | 3.13M | 11.69M | 0 |
| Financing Cash Flow | 28.55M | 120.31M | 178.96M | 391.82M | (378.47M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (34.62M) | 49.01M | 51.98M | 229.02M | (272.52M) |
| Free Cash Flow | (63.17M) | (71.3M) | (126.97M) | (162.8M) | 105.95M |
Keros Therapeutics, Inc.
NASDAQ:KROS
Intrinsic Alpha fair value
Locked
Current Price
$12.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.